With a proven track record of experience in healthcare diagnostics and oncology, the Vigilant Biosciences® leadership team is committed to transforming early cancer detection and improving outcomes.

Bill Brodie

Chief Executive Officer

Bill joined Vigilant Biosciences in the summer of 2018 as CEO to lead the Company’s transition from a development organization to a successful commercial enterprise.  Bill brings over 20 years of experience in management roles. Previously, he served as Chief Commercial Officer of Vital Connect, a leader in wearable biosensor technology for wireless hospital and remote patient monitoring.  He earlier served as Global Vice President of Sales and Marketing at myoscience where he built and led all commercial operations.  Bill also served as Vice President of Global Sales at Solta Medical.  From 1998 to 2006, Bill served as Vice President of Sales and Field Operations and held various sales management positions with Benco Dental, a $400M company specializing in dental office equipment sales, office design and supply management. His expertise includes team leadership, sales management and international business management.

Bill earned a Master of Science in Management from Georgia Institute of Technology and a Bachelor of Science in Mathematics from Rollins College.

Michael Donovan Ph.D., M.D.

Chief Medical Officer

Michael Donovan Ph.D., M.D. serves as the Chief Medical Officer of Vigilant Biosciences. Dr. Donovan is board-certified in anatomic and clinical pathology and pediatric pathology with extensive experience in designing and implementing clinical studies. He has spearheaded the utilization of multiplex tissue and fluid-based assays and coupled mathematical applications to produce clinically relevant diagnostic/predictive/prognostic outcome models for a variety of tumor types and disease states. Along with his clinical duties, Dr. Donovan also serves as a Professor of Experimental Pathology and Director of the Biorepository and Pathology core at the Icahn School of Medicine at Mt. Sinai, New York City, New York.

In addition to an academic career at Harvard Medical School and Boston Children’s Hospital, Dr. Donovan has over 20 years’ experience in the biotechnology industry, serving in various senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. He most recently served as Chief Medical Officer of MetaStat, Inc. and Chief Medical Officer of Exosome Diagnostics, Inc. where he served as laboratory director and was responsible for the implementation and execution of several clinical trials.

Dr. Donovan graduated from Rutgers University with a B.S. in zoology, a M.S. in endocrinology and a Ph.D. in cell and developmental biology with post-doctoral studies at Harvard Medical School. He received his M.D. from the University of Medicine and Dentistry of New Jersey.


Elizabeth Franzmann, M.D.

Scientific Founder and Chief Scientific Officer

Elizabeth Franzmann, M.D. serves as the Scientific Founder and Chief Scientific Officer of Vigilant Biosciences. Her innovative clinical research on selective salivary biomarkers for head and neck squamous cell carcinoma serves as the foundation for Vigilant Biosciences’ product line.

Dr. Franzmann’s work has been funded by foundations as well as state and federal agencies with the resulting research published in numerous, well-respected, and peer-reviewed journals. In addition to her clinical research activities, Dr. Franzmann is certified by the American Board of Otolaryngology specializing in otolaryngology and head and neck surgery as an Associate Professor of Otolaryngology at the University of Miami Miller School of Medicine. Dr. Franzmann has been recognized as one of the “Best Doctors in America,” an honor that reflects fellow physicians considering her to be one of the most skilled in her field and most qualified for reviewing complex medical conditions. Dr. Franzmann received her Bachelor of Science and Doctorate of Medicine at the University of California, Los Angeles.

Robert T. Hamilton, CPA

Chief Financial Officer

Robert T. Hamilton serves as the company’s Chief Financial Officer and VP of Administration. Mr. Hamilton is a former Big-Four CPA with 20+ years of public company and venture-backed private portfolio company experience having worked with companies in e-commerce, health and fitness, technology and retail/wholesale industries.

Prior to Vigilant Biosciences, Mr. Hamilton served as CFO of Bridgevine, Inc., a privately held and venture-backed e-commerce solution. Prior to that, he was the CFO of eDiets, Inc. (formerly NASDAQ- DIET), a leading provider of online weight loss solutions. Mr. Hamilton began his career as an auditor with Arthur Andersen, LLP in Boston. Progressing to audit manager, he serviced multinational SEC and non-public clients in the high technology, manufacturing, retail/wholesale distribution, and hospitality industries. Mr. Hamilton is a Certified Public Accountant and received his bachelor’s degree in Business Administration from Merrimack College.

Kris Foss

Vice President, Regulatory & Clinical

Kris joined Vigilant Biosciences in September 2018 and serves as Vice President, Regulatory & Clinical to support the Company’s commercial expansion, including its entry into the US market. Kris has over 25 years of experience in global regulatory management of complex medical device and combination products. She has held officer-level positions for entrepreneurial and established organizations, including Mentor Corporation (J&J) and Solta Medical (Bausch Health) where she led the company’s global regulatory, quality and clinical functions. Additionally, she has worked at several other leading medical device and pharmaceutical companies, successfully attaining international regulatory approvals, conducting complex clinical trials, and achieving quality objectives. Kris holds a Bachelor of Arts in Literature from Northwestern University and certification from the Regulatory Affairs Professionals Society (RAPS).

Tony Lavecchia

Head of Operations and Quality

Tony joined Vigilant Biosciences in September 2018 and serves as the Head of Operations and Quality to support the company’s commercial expansion, including its entry into the US market.  Tony has over 20 years of experience in operations, quality and product development in the pharma/biotech and medical device industries.  He has held Development, Operations and QC management positions for entrepreneurial and established organizations, including Beckman Coulter, Nuovo Biologics and Health-Chem Diagnostics (incl P-O-C dx kits) where he led the company’s R&D and production efforts.

Additionally,  Tony has consulted at several other pharma/biotech and med device companies, successfully attaining technical transfer for production, product/process development and validation and has implemented Quality Mgt systems.  Tony holds a Bachelor of Science in Chemistry from Florida International University and was a certified internal Tier II auditor at Beckman Coulter.